| Vol. 15.09 – 10 March, 2021 |
| |
|
|
| Researchers used an efficient multiplexing strategy to differentiate 215 human induced pluripotent stem cell lines toward a midbrain neural fate, including dopaminergic neurons, and used single-cell RNA sequencing to profile over one million cells across three differentiation time points. [Nature Genetics] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators showed that spinal cord injury (SCI) unveils a latent neurogenic potential of NG2+ glial cells, which could be exploited to produce new neurons and promote functional recovery after SCI. [Cell Stem Cell] |
|
|
|
| The authors report an activation mechanism of EGFR signaling in glioblastoma (GBM) by a secretory E-cadherin protein variant (C-E-Cad) encoded by a circular E-cadherin RNA through multiple-round open reading frame translation. C-E-Cad variant was overexpressed in GBM and promoted glioma stem cell tumorigenicity. [Nature Cell Biology] |
|
|
|
| Scientists report that the E4 allele of the apolipoprotein E gene (APOE4), but not APOE3, disrupted the cellular lipidomes of human induced pluripotent stem cell (iPSC)–derived astrocytes generated from fibroblasts of APOE4 or APOE3 carriers, and of yeast expressing human APOE isoforms. [Science Translational Medicine] |
|
|
|
| Both in vitro and in vivo data showed that neurotoxins, which phenotypically mimicked Parkinson’s Disease, increased TSPO to enhance cellular redox-stress, susceptibility to dopamine-induced cell death, and repression of ubiquitin-dependent mitophagy. [Molecular Psychiatry] |
|
|
|
| The authors used induced pluripotent stem cells to culture neuronal precursor cells and glutamatergic neurons from bipolar disorder patients characterized for lithium responsiveness and matched controls. [Molecular Psychiatry] |
|
|
|
| β-arrestin 1 (ARRB1) ablation ameliorated whereas ARRB2 knockout aggravated, the pathological features of Parkinson’s disease, including dopaminergic neuron loss, neuroinflammation, and microglia activation in vivo, and microglia-mediated neuron damage in vitro. [Cell Death & Differentiation] |
|
|
|
| Scientists identified a subpopulation of microglia named sMG2, which highly expressed necroptosis-related genes Rip3 and Mlkl. Genetic and pharmacological loss of function demonstrated that hypoxia-induced microglial activation committed to necroptosis through the RIP1/RIP3-mediated pathway. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| The authors found that EGFR expression began to sharply increase after gestational week 20, which corresponded to the beginning stages of human gliogenesis. [Cell Reports] |
|
|
|
| Investigators report that small extracellular vesicles secreted from primary astrocytes, but not from neurons or C6 glioma cells, greatly enhanced spine and synapse formation by primary cortical neurons. [Cell Reports] |
|
|
|
| Researchers hypothesized that the insertion of the A673T mutation in patients’ neurons could be an effective and sustainable method of slowing down or even stopping the progression of Alzheimer’s disease. [Molecular Therapy-Nucleic Acids] |
|
|
|
| Scientists adopted the AAV(2/8) delivery system to overexpress single factor Neurog2 into astrocytes and found that the majority of astrocytes were successfully converted into neuronal cells in multiple brain regions, including the midbrain and spinal cord. [Cell Death & Disease] |
|
|
|
|
| Investigators place a special emphasis on the heterogeneity of the tumor-associated microglia and macrophage populations present in primary brain tumors. [Nature Reviews Neurology] |
|
|
|
| Scientists examine past and present clinical and preclinical research into the neurobiological function of ARID1B. The presentation of ARID1B-related disorders is highly heterogeneous, including varying degrees of intellectual disability, autism spectrum disorder, and physical features. [Molecular Psychiatry] |
|
|
|
| The authors summarize mechanisms governing dopamine transporter (DAT) trafficking under normal physiological conditions and discuss how Parkinson’s disease-linked mutations may disturb DAT homeostasis. [npj Parkinson’s Disease] |
|
|
|
|
| Clene, Inc. announced that over 50% of participants have been enrolled in the HEALEY ALS Platform Trial being conducted at sites of the Northeast ALS consortium. [Clene, Inc.] |
|
|
|
| OncoSynergy, Inc. announced that the first patient was treated in the company’s First-in-Human Phase 1Iclinical trial evaluating OS2966 for the treatment of recurrent glioblastoma at Moffitt Cancer Center in Tampa, Florida. OS2966 is a first-in-class immunotherapy, and the first ever anti-CD29 therapeutic to reach human trials. [OncoSynergy, Inc. (PR Newswire. LLC)] |
|
|
|
|
| April 14 – 16, 2021 Virtual |
|
|
|
|
|
|
| Johns Hopkins University School of Medicine – Baltimore, Maryland. United States |
|
|
|
| Beth Israel Deaconess Medical Center – Boston, Massachusetts, United States |
|
|
|
| Flanders Institute for Biotechnology – Antwerp, Belgium |
|
|
|
| UC San Francisco – Location |
|
|
|
|